GlobeStar Therapeutics Accounts Payable

GlobeStar Therapeutics (GSTC) currently reports a accounts payable of $660K as of June 2024. That compares with $490K in the prior-year period — up 35.2% year over year. Use the charts on this page to explore GlobeStar Therapeutics's accounts payable history and peer comparisons.

GlobeStar Therapeutics's accounts payable increased from $490K to $660K — a 35.2% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

GlobeStar Therapeutics reported $660K in accounts payable as of June 2024. That compares with $490K in the prior-year period — up 35.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $660K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for GlobeStar Therapeutics, and consider following GSTC for alerts when major investors trade the stock.

GlobeStar Therapeutics is classified in the Industrials sector. On accounts payable, it currently shows $660K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing GSTC with unrelated industries.